In summary, PmTriTNE could activate T cells in the context of the TME, reverse PD‐L1 blockade to directly drive tumor cell lysis, and act synergistically with CDA to initiate an amplified immune cascade and thus achieve long‐term antitumor immunity against cold solid tumors. Here, CDA is linked to neoplasm.